Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide
Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQVTRS) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQVTRS) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Viatris Inc. (“Viatris” or the “Company”) (NASDAQVTRS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
12 large-cap stocks plummeted last week due to negative financial reports. These include SMCI, APP, CART, NTAP, PSTG, DUOL, VTRS, SRE, PLTR, TCOM, MSTR, and TSLA.
Shares of medication company Viatris (NASDAQVTRS)
fell 16.9% in the morning session after the company reported disappointing fourth-quarter 2024 results, with sales, earnings, and operating income all missing analysts' expectations. Sales came in soft, driven by strength in Greater China and new product launches, but weighed down by weaker performance in Developed and Emerging Markets. Looking ahead, Viatris' 2025 guidance also disappointed, with revenue and adjusted EBITDA projections falling short of expectations. The company expects an approximately $500 million revenue hit and a $385 million impact on adjusted EBITDA due to ongoing regulatory challenges at its Indore facility. Overall, this was a weaker quarter, and there were few positives to take away from the results.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
Let's delve into the developments on the US markets in the middle of the day on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Medication company Viatris (NASDAQVTRS) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 3.3% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 5.6% below analysts’ consensus estimates.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQVTRS).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Amneal (NASDAQAMRX).
Over the past six months, Viatris’s stock price fell to $10.77. Shareholders have lost 9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.3%. This might have investors contemplating their next move.
